453 related articles for article (PubMed ID: 34089011)
21. Emerging roles of miRNAs in the development of pancreatic cancer.
Fathi M; Ghafouri-Fard S; Abak A; Taheri M
Biomed Pharmacother; 2021 Sep; 141():111914. PubMed ID: 34328099
[TBL] [Abstract][Full Text] [Related]
22. Molecular pathology of pancreatic cancer.
Saiki Y; Horii A
Pathol Int; 2014 Jan; 64(1):10-9. PubMed ID: 24471965
[TBL] [Abstract][Full Text] [Related]
23. RB1 and TP53 co-mutations correlate strongly with genomic biomarkers of response to immunity checkpoint inhibitors in urothelial bladder cancer.
Manzano RG; Catalan-Latorre A; Brugarolas A
BMC Cancer; 2021 Apr; 21(1):432. PubMed ID: 33879103
[TBL] [Abstract][Full Text] [Related]
24. Integrative genomic and functional profiling of the pancreatic cancer genome.
Shain AH; Salari K; Giacomini CP; Pollack JR
BMC Genomics; 2013 Sep; 14():624. PubMed ID: 24041470
[TBL] [Abstract][Full Text] [Related]
25. Clinical Utility of Circulating Tumor DNA for Molecular Assessment and Precision Medicine in Pancreatic Cancer.
Takai E; Totoki Y; Nakamura H; Kato M; Shibata T; Yachida S
Adv Exp Med Biol; 2016; 924():13-17. PubMed ID: 27753011
[TBL] [Abstract][Full Text] [Related]
26. Clinical significance of genetic alterations in endoscopically obtained pancreatic cancer specimens.
Takano S; Fukasawa M; Shindo H; Takahashi E; Hirose S; Fukasawa Y; Kawakami S; Hayakawa H; Kuratomi N; Kadokura M; Maekawa S; Sato T; Enomoto N
Cancer Med; 2021 Feb; 10(4):1264-1274. PubMed ID: 33455072
[TBL] [Abstract][Full Text] [Related]
27. Convergent structural alterations define SWItch/Sucrose NonFermentable (SWI/SNF) chromatin remodeler as a central tumor suppressive complex in pancreatic cancer.
Shain AH; Giacomini CP; Matsukuma K; Karikari CA; Bashyam MD; Hidalgo M; Maitra A; Pollack JR
Proc Natl Acad Sci U S A; 2012 Jan; 109(5):E252-9. PubMed ID: 22233809
[TBL] [Abstract][Full Text] [Related]
28. Clinical significance of the genetic landscape of pancreatic cancer and implications for identification of potential long-term survivors.
Yachida S; White CM; Naito Y; Zhong Y; Brosnan JA; Macgregor-Das AM; Morgan RA; Saunders T; Laheru DA; Herman JM; Hruban RH; Klein AP; Jones S; Velculescu V; Wolfgang CL; Iacobuzio-Donahue CA
Clin Cancer Res; 2012 Nov; 18(22):6339-47. PubMed ID: 22991414
[TBL] [Abstract][Full Text] [Related]
29. Identification of Genomic Alterations in Sporadic Pancreatic Neurogenic Tumors.
Wang XY; Cai JP; Song LL; Huang CS; Chen W; Huang XT; Chen SF; Liu XY; Yin XY
Pancreas; 2020; 49(10):1393-1397. PubMed ID: 33122531
[TBL] [Abstract][Full Text] [Related]
30. [Will molecular diagnostics become established in pancreatic pathology?].
Sipos B; Sperveslage J
Pathologe; 2013 Nov; 34 Suppl 2():214-20. PubMed ID: 24196616
[TBL] [Abstract][Full Text] [Related]
31. Analysis of genomic alterations in cancer associated human pancreatic stellate cells.
Böker V; Häußler J; Baumann J; Sunami Y; Trojanowicz B; Harwardt B; Hammje K; von Auw N; Erkan M; Krohn K; Kleeff J
Sci Rep; 2022 Aug; 12(1):13532. PubMed ID: 35941161
[TBL] [Abstract][Full Text] [Related]
32. Pancreatic circulating tumor cell detection by targeted single-cell next-generation sequencing.
Yu J; Gemenetzis G; Kinny-Köster B; Habib JR; Groot VP; Teinor J; Yin L; Pu N; Hasanain A; van Oosten F; Javed AA; Weiss MJ; Burkhart RA; Burns WR; Goggins M; He J; Wolfgang CL
Cancer Lett; 2020 Nov; 493():245-253. PubMed ID: 32896616
[TBL] [Abstract][Full Text] [Related]
33. Targeting KRAS for diagnosis, prognosis, and treatment of pancreatic cancer: Hopes and realities.
Bournet B; Buscail C; Muscari F; Cordelier P; Buscail L
Eur J Cancer; 2016 Feb; 54():75-83. PubMed ID: 26735353
[TBL] [Abstract][Full Text] [Related]
34. A novel hotspot and rare somatic mutation p.A138V, at TP53 is associated with poor survival of pancreatic ductal and periampullary adenocarcinoma patients.
Saha G; Singh R; Mandal A; Das S; Chattopadhyay E; Panja P; Roy P; DeSarkar N; Gulati S; Ghatak S; Ghosh S; Banerjee S; Roy B; Ghosh S; Chaudhuri D; Arora N; Biswas NK; Sikdar N
Mol Med; 2020 Jun; 26(1):59. PubMed ID: 32552660
[TBL] [Abstract][Full Text] [Related]
35. Targeted next-generation sequencing of cancer genes dissects the molecular profiles of intraductal papillary neoplasms of the pancreas.
Amato E; Molin MD; Mafficini A; Yu J; Malleo G; Rusev B; Fassan M; Antonello D; Sadakari Y; Castelli P; Zamboni G; Maitra A; Salvia R; Hruban RH; Bassi C; Capelli P; Lawlor RT; Goggins M; Scarpa A
J Pathol; 2014 Jul; 233(3):217-27. PubMed ID: 24604757
[TBL] [Abstract][Full Text] [Related]
36. [Prognostic value of important driver gene mutations in patients with radical resection of pancreatic cancer].
Shen J; Gao SZ; Wang H; Shi XH; Li B; Pan YQ; Shen S; Shao Z; Guo SW; Jin G
Zhonghua Wai Ke Za Zhi; 2019 Nov; 57(11):840-847. PubMed ID: 31694133
[No Abstract] [Full Text] [Related]
37. Clinical correlates of blood-derived circulating tumor DNA in pancreatic cancer.
Patel H; Okamura R; Fanta P; Patel C; Lanman RB; Raymond VM; Kato S; Kurzrock R
J Hematol Oncol; 2019 Dec; 12(1):130. PubMed ID: 31801585
[TBL] [Abstract][Full Text] [Related]
38. Correlations between tumor mutation burden and immune infiltrates and their prognostic value in pancreatic cancer by bioinformatic analysis.
Cai Y; Wang X; Wang N; Wu J; Ma L; Xie X; Zhang H; Dang C; Kang H; Zhang S; Zhou Z
Life Sci; 2021 Jul; 277():119505. PubMed ID: 33872662
[TBL] [Abstract][Full Text] [Related]
39. Genome-wide somatic copy number alterations in low-grade PanINs and IPMNs from individuals with a family history of pancreatic cancer.
Hong SM; Vincent A; Kanda M; Leclerc J; Omura N; Borges M; Klein AP; Canto MI; Hruban RH; Goggins M
Clin Cancer Res; 2012 Aug; 18(16):4303-12. PubMed ID: 22723370
[TBL] [Abstract][Full Text] [Related]
40. Genome-wide sequencing to identify the cause of hereditary cancer syndromes: with examples from familial pancreatic cancer.
Roberts NJ; Klein AP
Cancer Lett; 2013 Nov; 340(2):227-33. PubMed ID: 23196058
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
